N
DNLI icon

Natixis’s Denali Therapeutics DNLI Stock Holding History

Natixis’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-69,030
Closed -$2.12M – 1156
2022
Q3 		$2.12M Hold
69,030
– – 0.01% 594
2022
Q2 		$2.03M Sell
69,030
-167,658
-71% -$4.39M 0.01% 662
2022
Q1 		$7.61M Sell
236,688
-56,866
-19% -$1.96M 0.03% 454
2021
Q4 		$13.1M Buy
293,554
+14,300
+5% +$677K 0.04% 326
2021
Q3 		$14.1M Buy
279,254
+69,556
+33% +$3.92M 0.05% 295
2021
Q2 		$16.4M Buy
209,698
+70,000
+50% +$4.33M 0.07% 215
2021
Q1 		$7.98M Sell
139,698
-151,000
-52% -$10.1M 0.03% 417
2020
Q4 		$24.3M Buy
290,698
+264,710
+1,019% +$16M 0.09% 227
2020
Q3 		$931K Buy
+25,988
New +$783K 0.01% 535

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Natixis's DNLI Position: Q4 2022 in Review

Natixis sold out of Denali Therapeutics (DNLI) in Q4 2022, closing a stake of 69,030 shares — an estimated $2.12M sold.

Natixis first reported a position in DNLI in Q3 2020 and held it in 9 quarters. The position peaked at $24.3M in Q4 2020. 197 funds tracked by Wall St. Rank hold DNLI as of Q4 2022.

  • Natixis reported no remaining Denali Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Natixis sold 69,030 Denali Therapeutics shares in Q4 2022, an estimated $2.12M.
  • Natixis first reported a position in Denali Therapeutics in Q3 2020 and held it in 9 quarters.
  • Natixis's Denali Therapeutics position peaked at $24.3M in Q4 2020.
  • 197 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2022.

Based on Natixis's 13F filing for Q4 2022, filed 13 Feb 2023.